SK18792000A3 - Spôsoby zvýšenia hladín acetylcholínu - Google Patents

Spôsoby zvýšenia hladín acetylcholínu Download PDF

Info

Publication number: SK18792000A3
Authority: SK; Slovakia
Prior art keywords: formula; compound; acid addition; optionally; ache
Prior art date: 1998-06-16

Application number

SK1879-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Henry Uhlman Bryant

Michele Annette Glinn

Steven Marc Paul

Xin Wu

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

1999-06-04

Publication date

2001-07-10

1999-06-04 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2001-07-10 Publication of SK18792000A3 publication Critical patent/SK18792000A3/sk

Links

OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 title claims abstract description 27
229960004373 acetylcholine Drugs 0.000 title claims abstract description 27
238000000034 method Methods 0.000 title abstract description 15
150000001875 compounds Chemical class 0.000 claims abstract description 45
241000124008 Mammalia Species 0.000 claims abstract description 16
108010058699 Choline O-acetyltransferase Proteins 0.000 claims description 26
102100023460 Choline O-acetyltransferase Human genes 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 19
108010022752 Acetylcholinesterase Proteins 0.000 claims description 17
229940022698 acetylcholinesterase Drugs 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 16
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 14
210000004556 brain Anatomy 0.000 claims description 14
210000005153 frontal cortex Anatomy 0.000 claims description 11
210000001320 hippocampus Anatomy 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
239000012453 solvate Substances 0.000 claims description 10
229940011871 estrogen Drugs 0.000 claims description 9
239000000262 estrogen Substances 0.000 claims description 9
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
150000001204 N-oxides Chemical class 0.000 claims description 5
230000002950 deficient Effects 0.000 claims description 5
229960003135 donepezil hydrochloride Drugs 0.000 claims description 5
XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 5
ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 claims description 5
229960002516 physostigmine salicylate Drugs 0.000 claims description 5
HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical group OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 claims description 5
229960003565 tacrine hydrochloride Drugs 0.000 claims description 5
239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000002411 adverse Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
102000012440 Acetylcholinesterase Human genes 0.000 claims 11
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 4
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
229940124596 AChE inhibitor Drugs 0.000 abstract description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
238000009472 formulation Methods 0.000 description 10
BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 7
229960002119 raloxifene hydrochloride Drugs 0.000 description 7
102100033639 Acetylcholinesterase Human genes 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
210000002932 cholinergic neuron Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000243 solution Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000033228 biological regulation Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
208000000044 Amnesia Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000003920 cognitive function Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
230000013016 learning Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
229940122041 Cholinesterase inhibitor Drugs 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
239000000969 carrier Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000002939 deleterious effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000006984 memory degeneration Effects 0.000 description 3
208000023060 memory loss Diseases 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000013223 sprague-dawley female rat Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
230000006949 cholinergic function Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
229950002007 estradiol benzoate Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000006386 memory function Effects 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
150000003577 thiophenes Chemical class 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
ZHJKRXYYBITCLF-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylethoxy)benzaldehyde;hydrochloride Chemical compound Cl.C1=CC(C=O)=CC=C1OCCN1CCCC1 ZHJKRXYYBITCLF-UHFFFAOYSA-N 0.000 description 1
PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000019771 cognition Effects 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000011194 food seasoning agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000036403 neuro physiology Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000008063 pharmaceutical solvent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229940102912 raloxifene hydrochloride 60 mg Drugs 0.000 description 1
238000011867 re-evaluation Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
-1 salt hydrochloride Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001836 utereotrophic effect Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

SK1879-2000A 1998-06-16 1999-06-04 Spôsoby zvýšenia hladín acetylcholínu SK18792000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8948998P	1998-06-16	1998-06-16
PCT/US1999/012525 WO1999065489A1 (en)	1998-06-16	1999-06-04	Methods for increasing levels of acetylcholine

Publications (1)

Publication Number	Publication Date
SK18792000A3 true SK18792000A3 (sk)	2001-07-10

Family

ID=22217929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1879-2000A SK18792000A3 (sk)	1998-06-16	1999-06-04	Spôsoby zvýšenia hladín acetylcholínu

Country Status (18)

Country	Link
US (1)	US6395719B1 (no)
EP (1)	EP0970695A1 (no)
JP (1)	JP2002518329A (no)
KR (1)	KR20010052891A (no)
CN (1)	CN1305377A (no)
AU (1)	AU751158B2 (no)
BR (1)	BR9911220A (no)
CA (1)	CA2335295A1 (no)
EA (1)	EA200100039A1 (no)
HR (1)	HRP20000862A2 (no)
HU (1)	HUP0102506A3 (no)
IL (1)	IL139015A0 (no)
NO (1)	NO20006087D0 (no)
PL (1)	PL344785A1 (no)
SK (1)	SK18792000A3 (no)
TR (1)	TR200003704T2 (no)
WO (1)	WO1999065489A1 (no)
ZA (1)	ZA200005887B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6288108B1 (en)	1998-06-16	2001-09-11	Eli Lilly And Company	Methods for increasing levels of acetylcholine
KR20010052891A (ko)	1998-06-16	2001-06-25	피터 지. 스트링거	아세틸콜린 수치를 상승시키는 방법
EP0976404A3 (en) *	1998-07-30	2001-06-27	Pfizer Products Inc.	A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
WO2005065645A2 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Donepezil formulations
GB0511003D0 (en) *	2005-05-28	2005-07-06	Univ Cardiff	Screening and treatment of alzheimer's disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0002097B1 (en)	1977-08-22	1981-08-05	Imperial Chemical Industries Plc	Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
TW366342B (en)	1992-07-28	1999-08-11	Lilly Co Eli	The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5554601A (en)	1993-11-05	1996-09-10	University Of Florida	Methods for neuroprotection
US6489355B2 (en)	1993-12-01	2002-12-03	Eli Lilly And Company	Methods of inhibiting the effects of amyloidogenic proteins
US5441965A (en)	1993-12-21	1995-08-15	Eli Lilly And Company	Methods of inhibiting thrombin
US5389670A (en)	1993-12-21	1995-02-14	Eli Lilly Company	Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5462950A (en)	1993-12-21	1995-10-31	Eli Lilly And Company	Methods of treating menstrual symptoms and compositions therefore
US5552415A (en)	1993-12-21	1996-09-03	Eli Lilly And Company	Method of inhibiting Alzheimer's Disease
WO1995017095A1 (en)	1993-12-21	1995-06-29	Eli Lilly And Company	Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5534526A (en)	1993-12-21	1996-07-09	Eli Lilly And Company	Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5578613A (en)	1993-12-21	1996-11-26	Eli Lilly And Company	Methods for inhibiting weight gain or inducing weight loss
US5604248A (en)	1994-05-05	1997-02-18	Eli Lilly And Company	Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5512296A (en)	1994-08-22	1996-04-30	Eli Lilly And Company	Methods for inhibiting neuronal damage
UA44710C2 (uk)	1995-02-28	2002-03-15	Елі Ліллі Енд Компані	Похідні бензотіофену, спосіб їх одержання (варіанти), проміжні сполуки, фармацевтична композиція
US5510357A (en)	1995-02-28	1996-04-23	Eli Lilly And Company	Benzothiophene compounds as anti-estrogenic agents
US5731342A (en)	1996-02-22	1998-03-24	Eli Lilly And Company	Benzothiophenes, formulations containing same, and methods
IL120269A0 (en)	1996-02-28	1997-06-10	Pfizer	1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
SI9720038B (sl)	1996-06-07	2010-06-30	Eisai Co Ltd	Polimorfi donepezil hidroklorida in postopek izdelave
ZA982877B (en)	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1999065309A1 (en)	1998-06-16	1999-12-23	Eli Lilly And Company	Methods for increasing levels of acetylcholine
KR20010052891A (ko)	1998-06-16	2001-06-25	피터 지. 스트링거	아세틸콜린 수치를 상승시키는 방법

1999
- 1999-06-04 KR KR1020007014236A patent/KR20010052891A/ko not_active Withdrawn
- 1999-06-04 SK SK1879-2000A patent/SK18792000A3/sk unknown
- 1999-06-04 AU AU43338/99A patent/AU751158B2/en not_active Ceased
- 1999-06-04 CN CN99807285A patent/CN1305377A/zh active Pending
- 1999-06-04 US US09/700,506 patent/US6395719B1/en not_active Expired - Fee Related
- 1999-06-04 HR HR20000862A patent/HRP20000862A2/hr not_active Application Discontinuation
- 1999-06-04 CA CA002335295A patent/CA2335295A1/en not_active Abandoned
- 1999-06-04 IL IL13901599A patent/IL139015A0/xx unknown
- 1999-06-04 TR TR2000/03704T patent/TR200003704T2/xx unknown
- 1999-06-04 JP JP2000554369A patent/JP2002518329A/ja not_active Withdrawn
- 1999-06-04 EA EA200100039A patent/EA200100039A1/ru unknown
- 1999-06-04 WO PCT/US1999/012525 patent/WO1999065489A1/en not_active Ceased
- 1999-06-04 PL PL99344785A patent/PL344785A1/xx unknown
- 1999-06-04 BR BR9911220-5A patent/BR9911220A/pt not_active IP Right Cessation
- 1999-06-04 HU HU0102506A patent/HUP0102506A3/hu unknown
- 1999-06-11 EP EP99304587A patent/EP0970695A1/en not_active Withdrawn
2000
- 2000-10-20 ZA ZA200005887A patent/ZA200005887B/en unknown
- 2000-11-30 NO NO20006087A patent/NO20006087D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR200003704T2 (tr)	2001-06-21
IL139015A0 (en)	2001-11-25
HUP0102506A2 (hu)	2002-01-28
EA200100039A1 (ru)	2001-06-25
NO20006087L (no)	2000-11-30
AU4333899A (en)	2000-01-05
JP2002518329A (ja)	2002-06-25
EP0970695A1 (en)	2000-01-12
HRP20000862A2 (en)	2001-10-31
ZA200005887B (en)	2002-07-22
BR9911220A (pt)	2001-03-06
HUP0102506A3 (en)	2003-01-28
PL344785A1 (en)	2001-11-19
KR20010052891A (ko)	2001-06-25
CN1305377A (zh)	2001-07-25
NO20006087D0 (no)	2000-11-30
AU751158B2 (en)	2002-08-08
CA2335295A1 (en)	1999-12-23
US6395719B1 (en)	2002-05-28
WO1999065489A1 (en)	1999-12-23

Publication	Publication Date	Title
PL177348B1 (pl)	1999-10-29	Środek farmaceutyczny do stosowania w inhibitowaniu ubytku kości u ludzi
EP0736007A1 (en)	1996-10-09	Non-peptide tachykinin receptor antagonists
JPH07215855A (ja)	1995-08-15	自己免疫疾患を抑制する方法
JPH07215858A (ja)	1995-08-15	機能障害性子宮出血を抑制する方法
HUT71228A (en)	1995-11-28	Pharmaceutical compositions against, ovarian dysgenesis, delayed puberty or sexual infantilism containing 2-phenyl-3-aroyl-benzotiophene-derivatives and process for their preparation
CZ322194A3 (en)	1995-08-16	Pharmaceutical preparation for inhibiting turner syndrome
MXPA01010904A (es)	2002-06-21	Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion del conjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos a
SK18792000A3 (sk)	2001-07-10	Spôsoby zvýšenia hladín acetylcholínu
SK18812000A3 (sk)	2002-01-07	Spôsoby zvyšovania hladín acetylcholínu
US6288108B1 (en)	2001-09-11	Methods for increasing levels of acetylcholine
US6353003B1 (en)	2002-03-05	Method for reducing levels of homocysteine and C-reactive protein
US20010041745A1 (en)	2001-11-15	Methods for increasing levels of acetylcholine
MXPA05001919A (es)	2005-06-03	Sales de pamoato de piperidin-2,6-diona y su uso para tratamiento de trastornos afectivos relacionados con estres.
CZ20004699A3 (cs)	2001-06-13	Způsoby zvyšování hladiny acetylcholinu
MXPA00011284A (en)	2001-07-31	Methods for increasing levels of acetylcholine
MXPA00010458A (en)	2001-07-31	Methods for increasing levels of acetylcholine
CZ20004700A3 (cs)	2001-04-11	Způsob zvyšování hladin acetylcholinu
JPH07215866A (ja)	1995-08-15	男性不妊症を抑制する方法
CZ20004701A3 (cs)	2001-05-16	Způsoby snižování hladin homocysteinu a Creaktivního proteinu